NetQin Mobile Inc. (NYSE:NQ) announced its unaudited financial results for the second quarter ended June 30, 2011. Net revenues increased 147.4% year-over-year to $8.9 million from $3.6 million in the corresponding period of 2010, exceeding the high end of the Company’s previous guidance. Income from operations, or operating income, increased 241.7% year-over-year to $0.5 million from $0.14 million in the corresponding period of 2010. Non-GAAP operating income, defined as operating income excluding share-based compensation expenses, increased 727.4% year-over-year to $3.7 million from $0.45 million in the corresponding period of 2010.
NetQin Mobile Inc. operates as a software-as-a-service provider of consumer-centric mobile Internet services focusing on security and productivity in the People Republic of China and internationally.
Cleantech Transit Inc. (�Cleantech�) (OTC.BB:CLNO) was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company�s manufacturing clients worldwide.
The technology used by Phoenix Energy to turn your waste from industry agriculture and forestry into power has many environmental benefits. At Phoenix Energy we are deeply committed to our customers both in reducing their costs of operation and in helping them be good corporate citizens, having a positive impact on the environment. By installing our wood waste gasification systems our customers help to:
� Reduce greenhouse gas emissions
� Reduce the amount of toxic pollutants in the atmosphere
� Save landfill space from taking up more of our landscape and Reduce groundwater
contaminants
� Improve energy security and reduce dependence on foreign sources of energy
Cleantech Transit, Inc. is pleased to announce it has met its funding requirement to secure the Company�s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move
To discover more about CLNO, Please visit: http://www.cleantechtransitinc.com/
-First in a new class of ADCs to be FDA-approved-
-Seattle Genetics to implement comprehensive reimbursement support and patient assistance program-
-Conference call Monday, August 22, 2011, at 8:30 a.m. ET to provide further information on the launch and commercialization of ADCETRIS-
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ADCETRIS(TM) (brentuximab vedotin) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS. ADCETRIS is the first drug approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic ALCL in these settings. Seattle Genetics expects to make ADCETRIS available to patients next week. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
Seattle Genetics also announced that it has established a patient assistance program named SeaGen Secure� that offers patients and providers access to ADCETRIS reimbursement support, benefit investigations and patient assistance programs. More information about SeaGen Secure is available at (855)-4SEAGEN (855-473-2436) Monday through Friday from 9:00 a.m. to 8:00 p.m. Eastern Time.
The recommended dose of ADCETRIS is 1.8 milligrams per kilogram administered only as an intravenous infusion over 30 minutes every three weeks. Treatment should be continued until a maximum of 16 cycles, disease progression or unacceptable toxicity.
Conference Call Details
Seattle Genetics� management will host a conference call and webcast to discuss the approval, the price of ADCETRIS, and the company�s reimbursement and patient assistance program. The call will be held Monday, August 22, 2011 at 5:30 a.m. Pacific Time (PT); 8:30 a.m. Eastern Time (ET). The live event will be available from Seattle Genetics� website at www.seattlegenetics.com, under the Investors and News section, or by calling (877) 941-8609 (domestic) or (480) 629-9818 (international). The access code is 4466950. A replay of the discussion will be available beginning at approximately 7:30 a.m. PT on August 22, 2011 from Seattle Genetics� website or by calling (800) 406-7325 (domestic) or (303) 590-3030 (international), using access code 4466950. The telephone replay will be available until 5:00 p.m. PT on August 24, 2011.
More information about ADCETRIS is available at (855)-4SEAGEN (855-473-2436) Monday through Friday from 9:00 a.m. to 8:00 p.m. Eastern Time.
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Seattle Genetics� first product, ADCETRIS�, was approved by the FDA on August 19, 2011 for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen. In addition to ADCETRIS, Seattle Genetics has three other clinical-stage programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab.
More information can be found at www.seattlegenetics.com.
China Yuchai International Limited (NYSE:CYD) announced its unaudited consolidated financial results for the second quarter and six months ended June 30, 2011. Net revenue was RMB 4.0 billion (US$ 620.7 million); Total number of diesel engine units sold was 139,236 compared with 132,092 units in the second quarter of 2010;The gross margin was 19.2%, down from 22.3% in the second quarter of 2010.
China Yuchai International Limited, through its subsidiaries, manufactures and sells diesel and natural gas engines in China and internationally.
Delek US Holdings, Inc. (NYSE:DK) declared a quarterly cash dividend of $0.0375 per share, payable on September 21, 2011, to shareholders of record on August 24, 2011. Delek US Holdings, Inc. is a diversified downstream energy business focused on petroleum refining, the wholesale distribution of refined products and convenience store retailing. The refining segment consists of refineries operated in Tyler, Texas and El Dorado, Arkansas with a combined nameplate production capacity of 140,000 barrels per day.
Delek US Holdings, Inc. engages in refining, wholesaling, and marketing petroleum products in the United States. The company operates through three segments: Refining, Marketing, and Retail.
No comments:
Post a Comment